Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma

NCT05938387 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

BIOLOGICAL: CV09050101 mRNA vaccine (CVGBM) 12 μg
BIOLOGICAL: CV09050101 mRNA vaccine (CVGBM) 25 μg
BIOLOGICAL: CV09050101 mRNA vaccine (CVGBM) 50 μg
BIOLOGICAL: CV09050101 mRNA vaccine (CVGBM) 100 μg
BIOLOGICAL: CV09050101 mRNA vaccine RDE 100 μg
BIOLOGICAL: CV09050101 mRNA vaccine (CVGBM) 6 μg

Sponsor

CureVac